NGM Biopharmaceuticals
IPO News: Filed S-1: NGM Biopharmaceuticals files $75mm IPO
NGM Biopharmaceuticals

NGM Biopharmaceuticals

NASADQ: NGM

Initial Filing Date:  09/28/18

Size:  $75mm

Bookrunners:  GS | CITI | COWN

Major Holders:  The Column Group (Director, David V. Goeddel) | Merck Sharp & Dohme Corp | Prospect Ventures | Topspin Fund | Rho Ventures | Executives & Directores

Description:  NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics based on our scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases.

Note: Emerging Growth Company; This offering includes a directed share program

 

 

Reference Link: S-1